TIDMIXI

RNS Number : 8310C

IXICO plc

22 October 2020

IXICO plc

("IXICO" or the "Company")

Further Huntington's disease contracts

Additional Huntington's disease contracts with new and existing large pharma clients

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington's disease (HD) clinical trials.

The new contracts include retrospective analysis of data sets for three Natural History Studies in Huntington's disease with a new large pharma customer and a multicentre, open-label Phase II study in Huntington's disease with an existing large pharma customer.

Whilst these contracts to support HD clinical trials are not to the same scale as the GBP10.5m contract announced in April 2020, these additional contracts reflect the strong position IXICO has as a trusted neuroscience technology partner in this area. These contracts do not have significant impact on management's expectations of performance for the year but contribute to the Company's strong order book. In addition to this, these contracts are for early stage clinical trials and, as already demonstrated, IXICO has a strong track record of following clinical assets through to phase III where the contracts generate greater revenues.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "Huntington's disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on several HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development ."

For further information please contact:

 
 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales) 
 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
  / 
 Alice Woodings 
 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTEASEFAFPEFFA

(END) Dow Jones Newswires

October 22, 2020 02:00 ET (06:00 GMT)